Table 2.
Disease activity, B-cell status, BAFF, and APRIL at all time points in patients with RA
| ID | R1 | R3 | R7 | R9 | R11 | R14 | R15 | R16 | R17 | |
| Age (in years)/gender | 38/F | 73/M | 60/F | 64/F | 60/F | 66/F | 63/F | 60/F | 58/M | |
| DAS28 | Baseline | 6.78 | 8.14 | 5.69 | 5.81 | 7.69 | 6.48 | 7.4 | n.d. | 5.52 |
| Depletion | 4.42 | 5.43 | n.d. | 3.84 | n.d. | n.d. | 1.97 | 1.93 | n.d. | |
| 6 months post-treatment | 3.14 | 4.41 | 2.89 | 2.51 | 4.51 | 3.01 | ||||
| Percentage of CD19+ B cells | Baseline | 1 | 4 | 4 | 8 | 7.6 | 1.7 | 6 | 9.6 | 7 |
| Depletion | bdl | bdl | n.d. | bdl | bdl | bdl | bdl | bdl | bdl | |
| 6 months post-treatment | 0.5 | bdl | bdl | bdl | 1 | |||||
| CD19+ B cells × 109 per litre | Baseline | 0.02 | 0.05 | 0.04 | 0.14 | 0.19 | 0.01 | 0.06 | 0.18 | 0.08 |
| Depletion | bdl | bdl | n.d | bdl | bdl | bdl | bdl | bdl | bdl | |
| 6 months post-treatment | bdl | bdl | bdl | bdl | 0.01 | bdl | ||||
| BAFF (ng/ml) | Baseline | 1.01 | 3.42 | 0.92 | 0.75 | 1.33 | 1.31 | 1.90 | 2.30 | 1.08 |
| Depletion | 4.27 | 7.90 | n.d. | 2.62 | n.d. | 4.06 | 3.12 | 3.51 | 4.41 | |
| 6 months post-treatment | 5.88 | 6.34 | 4.46 | 2.83 | 1.59 | |||||
| APRIL (ng/ml) | Baseline | 409 | 77.8 | 189 | 5.04 | 96.7 | 124 | 179 | 23.7 | 39.5 |
| Depletion | 412 | 54.3 | n.d. | 2.53 | n.d. | 112 | 160 | 38.2 | 61.7 | |
| 6 months post-treatment | 419 | 32.0 | 113 | 1.12 | 97.1 |
APRIL = a proliferation-inducing ligand; BAFF = B-cell activation factor of the tumour necrosis factor family; bdl = below detection limit; DAS28, disease activity score using 28 joint counts; F, female; M, male; n.d., not determined; RA, rheumatoid arthritis.